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ABSTRACT 
The aim of the study was to design sustained release  matrix tablets of Venlafaxine Hydrochloride using a  high 
permeable Eudragit RLPO and low permeable Eudragit RSPO in different ratios. Tablet matrices were prepared by 
direct compression and were formulated as F1, F2 and. F3 by using the above mentioned polymers. Technological 
characterizations like thickness, diameter, weight variation test, drug content, hardness, and friability were carried out 
with the formulated matrix tablet. The in-vitro drug releases of the formulated tablets were measured using the USP -
24 types II dissolution apparatus. The formulations showed an optimum hardness, constant weight uniformity and 
low friability. The kinetic release treatment showed that the release of drug follows Zero order kinetic (r
2 = 0. 9965), 
Koresmeyer equation gave value of r
2= 0.9980 which was close to one indicating that the drug was released by Zero 
order kinetic. The in- vitro drug release data to Koresmeyer equation indicated that diffusion along with erosion could 
be the mechanism of drug release. The formulation F1 containing high quantity of Eudragit RSPO provided the 
slowest  release  profile  and  90  % of  the  drug  content  was released  after  18  hours than  other  formulations.  The 
systematic formulation approach enabled to develop sustained release Venlafaxine Hydrochloride tablets. 
Further investigations are needed to confirm the in vivo efficacy and this study demonstrated that Eudragit polymer 
can provide controlled release  
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INTRODUCTION 
Venlafaxine  hydrochloride,  novel  antidepressants,  is 
referred  to  as  a  serotonin-nor  epinephrine-dopamine 
reuptake inhibitor
1, 2. It works by blocking the transporter 
“reuptake”  proteins  for  key  neurotransmitter  affecting 
mood, thereby  leaving  more  active  neurotransmitter  in 
the synapse. The neurotransmitters affected are serotonin 
15-hydroxy  tryptamine  and  nor  epinephrine 
(noradrenalin). It is widely prescribed for the treatment 
of  depression,  generalized  anxiety  disorder,  and  social 
anxiety  disorder.  The  recommended  oral  dosages  of 
Venlafaxine hydrochloride are typically in the range of 
75 to 225mg per day. Because of its relatively short half-
life  of  5  hour,  Venlafaxine  should  be  administered  in 
divided dosages throughout the day
3. Its short biological 
half-life (5hr), calls for frequent daily dosing (2-3 times) 
and  therapeutic  use  in  antidepressant  necessitates  its 
formulation into sustained release dosage.                      
Plastic  polymers  examples  acrylate  and  ethyl  cellulose 
are capable of forming insoluble or skeleton matrices are 
widely used for controlled release of drugs due to their 
inertness and drug embedding ability. Liquid penetration 
into  the  matrix  is  the  rate  controlling  step  in  such 
systems, unless channeling agents are used.
4. 
Acrylic polymers are widely used as tablet retardants and 
as  coatings  of  drug  release  in  sustained  release 
formulation
5. The  most  interested acrylic polymers are 
highly  permeable  Eudragit  RLPO  and  low  permeable 
Eudragit RSPO, both of which are neutral copolymers of 
poly  (ethyl  acrylate,  methyl  metha  acrylate)  and 
trimethyl amino ethyl methacrylate chloride. These are 
insoluble  in  water  and  digestive  juices,  but they  swell 
and are permeable, which means that drugs embedded in 
their matrices can be released by diffusion 
6. Therefore, 
the permeability of drug through Eudragit RSPO and or 
RLPO  is  independent of the pH of the digestive tract. 
The  degree  of  permeability  depends  on  the  relative Radhika P R et al / IJRAP 2011, 2 (4) 1386-1389 
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proportion of quaternary ammonium groups in Eudragit. 
The  proportion  of  functional  quaternary  ammonium 
groups in Eudragit RL and Eudragit RS is 10% and 5% 
respectively. Eudragit RLPO and RSPO are fine, white 
powders with a slight amine like odour. 
The  present  research  was  directed  towards  the 
development  of  sustained  release  dosage  form  of 
Venlafaxine hydrochloride tablets using Eudragit RSPO 
and  Eudragit  RLPO  as  plastic  matrix  to  retard  drug 
release. 
MATERIALS AND METHODS   
Venlafaxine  hydrochloride  was  obtained  from  Orchid 
Pharmaceuticals, Chennai, Eudragit RSPO and Eudragit 
RLPO  was  procured  from  Rohm  Pharma,  Germany, 
Lactose, magnesium stearate and talc was of IP grades. 
All other  ingredients used throughout the study are of 
analytical grade and were used as received. 
Preparation  of  Sustained  Release  Venlafaxine 
Hydrochloride Matrix Tablets 
Matrix  tablet,  each  containing  37.5  mg  Venlafaxine 
hydrochloride,  was  prepared  by  direct  compression 
technique. The drug polymer ratios were developed to 
adjust drug release (Table-1) and to keep total weight of 
tablet  constant  for  all  the  fabricated  batches  under 
experimental conditions of preparations. The total weight 
of the  matrix tablets were 400  mg  with different drug 
polymer (Eudragit RSPO and Eudragit RLPO) ratios. A 
batch of 100 tablets was prepared  in each  formulation 
(F1 – F3). The compositions of tablets are shown in the 
(Table-1) and the ingredients were passed through sieve 
no:  30  and  thoroughly  mixed.  The  powder  blend  was 
then lubricated with Aerosil, talc and magnesium stearate 
and compressed into tablets on a single punch 10 mm 
diameter tablet compression machine. 
Evaluation of Tablets 
The prepared matrix tablets were evaluated for hardness, 
weight variation, thickness, friability and drug content. 
Hardness  of  tablets  was  tested  using  Monsanto-tester, 
friability  of  the  tablet  was  determined  in  a  Roche 
Friabilator.  The  thickness  of  tablet  was  measured  by 
using  vernier  calipers.  Weight  variation  test  was 
performed  according to official  method
7. Drug content 
for  Venlafaxine  Hydrochloride  was  carried  out  by 
measuring  the  absorbance  of  samples  at  224nm  using 
UV-Visible  spectrophotometer  and  comparing  the 
content from the calibration curve prepared with standard 
curve of Venlafaxine hydrochloride (Table-2). 
In-vitro Drug Release Studies  
The  in-vitro dissolution  studies were  carried out using 
USP 24 dissolution Apparatus type- II 
8 (paddle method 
at 100 rpm). Dissolution test was carried out for a total 
period of 24 hours using 0.1 HCl (pH1.2) solution with 
900 ml as dissolution medium at 37 ± 0.5
oc for first 2 
hours, and pH 7.2 phosphate buffer solution 900ml for 
the rest of the period .5ml of the sample was withdrawn 
at regular intervals and replaced with the same volume of 
pre  warmed  (37  ±
  0.5)  fresh  dissolution  medium.  The 
samples  withdrawn  were  filtered  through  0.45  µ 
membrane  filter  and  drug  content  in  each  sample  was 
analyzed  after  suitable  dilution  by  above  mentioned 
spectrophotometer  at  224  nm.  The  actual  content  in 
samples was read from a calibration curve prepared with 
standard Venlafaxine hydrochloride (Figure- 1). 
Kinetic Analysis of Dissolution Data 
The commonly adopted model of understanding release 
behavior  of  a  drug  from  hydrophilic  matrix  is  by  a 
simple exponential equation
9. The in-vitro drug release 
data were fitted in the experimental equation known as 
Korsmeyer  -  peppas  equation  Mt/M∞=Kt
n,  where  Mt 
corresponds to the amount of drug release in time t, M∞ 
is the total amount of drug released after an infinite time, 
K  is a constant related to the structural and geometric 
properties  of  the  drug  delivery  system  and  ‘n’  is  the 
release exponent related to the mechanism of the release. 
Table  -3  shows  an  analysis  of  diffusional  release 
mechanism obtained by various values of ‘n’
10 The ‘n’ 
values  used  for  elucidation  of  the  drug  release 
mechanisms from the tablets were determined from log 
cumulative percentages of drug released verses log time 
plots (ie, log Mt/M∞ ×100) verses log t. 
Stability Studies    
The selected fabricated tablet was kept at 45°c with 75% 
RH. Samples were withdrawn at 0, 15, 30 and 45 days 
for evaluation of appearance, drug content and in-vitro 
drug release. 
RESULT AND DISCUSSION 
For  a  freely  soluble  drug  like  Venlafaxine 
Hydrochloride, a rapid rate of hydration of matrix agent 
is necessary. A slow polymer hydration rate may lead to 
dose  dumping  due  to  quick  penetration  of  dissolution 
fluid  in  the  tablet  core.  Hence  a  rapidly  permeable 
Eudragit RLPO and low permeable Eudragit RSPO were 
used  as  polymers,  for  preparing  the  sustained  release 
matrix  tablet  of  Venlafaxine  Hydrochloride  by  direct 
compression.  
The  prepared  tablets  were  subjected  to  different 
evaluation tests based on USP. The drug content of each 
tablet should be in the range of 85 % – 115%. According 
to the above said results, the drug content distribution of 
each  formulation  was  uniform.  All  the  formulations 
showed good uniformity in drug content. 
Results of tablet hardness test showed that the hardness 
and friability of all formulations were in a range from 5 – 
7  kg/cm
2  and  0.39%  –  0.41%  respectively.  The  tablet Radhika P R et al / IJRAP 2011, 2 (4) 1386-1389 
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hardness for all formulations was in the required limits. 
The hardness of the tablet increased proportionately with 
the  amount of  Eudragit  RLPO  and  Eudragit  RSPO.  A 
small difference between formulations is related to the 
type  and  percentage  of  the  retarding  polymer.  Since 
tablet  hardness  is  not  a  perfect  index  to  evaluate  the 
strength  of  tablets,  friability  was  also  used  to test  the 
hardness  of  tablets.  For  all  the  prepared  formulations, 
friability percentage was less than 1 %, which was in the 
acceptable range. 
According  to  the  pharmacopeial  recommendation  for 
tablets weighing more than 324 mg ± 5 % deviation from 
the  mean  weight  is  acceptable.  The  results  show,  the 
average weight deviation percentage of 20 tablets taken 
from each formulation was less than ± 0.5 %, and all the 
formulations met the official requirements (Table -2). 
Drug Release Studies 
When  matrices  containing  swellable  polymers  are 
exposed to dissolution medium, tablet surface becomes 
wet and hydrated to form a gel layer. The initial release 
of  drug  from  these  matrices  occurs  by  the  drug 
dissolution in the water penetrated into the matrix. The 
overall drug release from these matrices is governed by 
hydration, gel layer formation, drug diffusion into the gel 
layer and to the dissolution media
11, 12   
Polymer  erosion  also  plays  a  major  role  in  release  of 
drugs  from  these  matrices
13.  These  considerations 
indicate that hydrophilic polymers have the potential to 
sustain the release of drug from matrix tablets. 
pH independent compressible Eudragit RSPO and RLPO 
were  used  for  preparation  of  matrix  tablets.  Eudragit 
RSPO and RLPO are freely flowable powders which can 
be used for direct incorporation within the matrix. 
The formulation F1 containing high quantity of Eudragit 
RSPO provided the slowest release profile and 90 % of 
the drug content was released after 18 hrs. This in turn 
resulted in a delayed water penetration and gelling of the 
polymer, where as in the formulation F3 the release of 
drug  increased  with  increase  in  the  proportion  of 
Eudragit RLPO and decrease in the presence of Eudragit 
RSPO.  This  is  due  to the  increase  in  the  solubility  of 
drug as a result of the presence of a more hydrophilic 
carrier  surrounding  the  drug  particles.  This  can  be 
attributed to the hydrophilic nature of Eudragit RLPO. 
When  exposed  to  the  dissolution  medium,  the  solvent 
penetrates  into  the  free  spaces  between  the 
macromolecular spaces of Eudragit RLPO. 
In  conclusion  the  formulation  F1  prepared  with  more 
quantity  of  Eudragit  RSPO  seems  to  produce  a  more 
appropriate  sustained  release  profile  than  other 
formulations.  As observed  in  Fig- 1, the release of  F1 
Eudragit  RSPO120  mg  and  Eudragit  RLPO  80  mg 
sustained the release of the drug up to 18 hours i.e. up to 
90  %,  which  indicates  that  by  increasing  the 
concentration of the Eudragit RSPO, drug release may be 
sustained more than 18 hours. 
The  formulation  F1  best suited with  zero order release 
kinetics (0.9965) than the first order release kinetics. The 
Koresmeyer  peppas  drug  release  kinetics  showed 
correlation coefficient (0.9980) and release exponent (n) 
0.9272 which indicates that the drug release mechanism 
is Fickian diffusion (Table- 3)   
CONCLUSION 
Venlafaxine  Hydrochloride  tablets  were  prepared  by 
direct compression using Eudragit RSPO  and Eudragit 
RLPO in different ratios. These polymers have potentials 
for  aiding  the  formulation  of  sustained  release 
Venlafaxine Hydrochloride matrix tablets. The approach 
of  the  present  study  was  to  make  a  comparative 
evaluation among the methacrylic esters polymers and to 
find  out  factors  involved  on  drug  release  profile.  By 
using these polymers, sustained release dosage form of 
Venlafaxine Hydrochloride would not only increase the 
efficacy  of  treatment  and  patient  compliance,  but  also 
produce desirable blood concentrations and decrease the 
incidence of adverse effects. 
Finally it can be concluded that study have established a 
feasibility  of  formulating  a  sustained  release  matrix 
tablet of Venlafaxine Hydrochloride with different ratios 
of  Eudragit  RSPO  and  Eudragit  RLPO  and  further 
studies could be carried out from these formulations. 
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Table- 1: Drug and polymer composition of different formulations 
 
S.No  Ingredients  F1(mg)  F2(mg)  F3(mg) 
1.  Drug  37.5  37.5  37.5 
2.  Eudragit RSPO  120  80  40 
3.  Eudragit RLPO  80  120  160 
4.  Lactose  140.5  140.5  140.5 
5.  Talc  12  12  12 
6.  Magnesium stearate  6  6  6 
7.  Aerosil  4  4  4 
 
Table: 2 Physical parameters of fabricated Venlafaxine Hydrochloride Matrix tablets 
 
S.No.  Hardness (kg/cm
2)  Friability (%)  Weight Variation (%)  Drug Content (%)  Thickness (mm) 
F1  6.5±0.15  0.41  0.19  37.53±0.32  4.75 mm 
F2  7.0±0.10  0.39  0.14  37.50±0.31  4.74 mm 
F3  5.0±0.12  0.57  0.16  37.54±0.33  4.73 mm 
 
Table: 3 Mathematical Modeling and Drug release kinetics of Venlafaxine Hydrochloride for the Formulated matrix tablets 
 
FORMULATIONS  ZERO ORDER  PEPPAS PLOT 
R  ‘n’  R 
F1  0.9965  0.9272  0.9980 
F2  0.9913  0.8031  0.9944 
F3  0.9810  0.6925  0.9876 
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Figure: 1 Graph showing the in-vitro release profile of Venlafaxine Hydrochloride for the Formulated matrix tablets 
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